Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) has shared an update.
AstraZeneca Pharma India Limited has announced it will discontinue the manufacturing and marketing of Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg, known as Imdur, effective April 1, 2025. This decision impacts the availability of Imdur, which is used for the prophylactic treatment of angina pectoris, potentially affecting patients and healthcare providers relying on this medication.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of prescription medicines. The company is a key player in the healthcare sector, providing a wide range of products aimed at treating various medical conditions.
YTD Price Performance: 17.87%
Average Trading Volume: 2,115
Current Market Cap: 212.3B INR
For an in-depth examination of ASTRAZEN stock, go to TipRanks’ Stock Analysis page.